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Seizures in the Intensive Care Unit
Etiology
Furthermore, significant clinical sequelae from
seizures usually occur as a resultofcomplications such
as aspiration or trauma during the seizure, or cortical
damage from a prolonged, unremitting course. Thus, it
is mandatory to treat them vigorously and effectively.
S. K. Gupta, Ashok Parihar
Introduction
Seizures are a relatively common neurological
complication in patients admitted to an Intensive Care
Unit (ICU) environment. A review by Black et al. noted
that approximately 12%ofpatients admitted with a non-
neurological primary diagnosis incurred neurological
events duringtheircritical illnessand outofthis seizures
constituted 28.1 % (I). Since the incidence ofseizures
It must be emphasized that in the vast majority of occurs most often in non-primary neurological patients,
cases, seizures occurring in the ICU are easily treated, it is important for the general clinician, intensivist, and
and the focus of attention is toward identifying the consulting neurologist to be well versed about seizures
and their treatment in the ICU. etiology and to prevent recurrence. As listed below
(Table I)manyconditions predispose to loweringofthe
The ICU environment unfortunately presents unique
seizure threshold. Since seizures may occur in virtually
challenges and difficulties with regards to the etiology,
any individual given appropriate triggers, the clinician
diagnosis and management of seizures. Because the
must playdetective in determining which etiologicfactor
patients are :-
is responsible.
(I) critically ill, frequently with multiple organ
Some of the most common causes of seizures in a dysfunction presenting a variety ofpotential
medical ICU are sepsis and cardiovascular disease (I). etiologies for cerebral disturbance.
In addition, patients suffering from metabolic
(2) treated with sedatives and paralytics that
abnormalities and acute drug withdrawal also comprise
prevent good neurological examination.
a high percentage of patients with new-onset seizures
(3) presented with a variety oftherapeutic drugs (2). Metabolic abnormalities, in fact, may be responsible
that may lower seizure threshold, and for up to 30-35% ofseizures in critically ill patients (2).
(4) in an environment that hinders optimal EEG The most common specific etiologies include
recording conditions. hyponatremia, uremia, and hypoglycemia. In patients
All these factors work against the clinician 111 the with a primary neurological disorder, tumors, ischemic
prevention and managementofseizures in an ICU setting. stroke, intracerebral hemorrhage, CNS infections, -------------
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etc., all have a relatively high associated incidence of
seizures.
Other causesofseizures in the ICU are drugs which
are used commonly, though the medications rank fairly
low as a risk for precipitatingseizures. The large Boston
Collaborative Drug Surveillance Programme evaluating
the records of 32,812 in patients, found drug-induced
seizures to occur in only 0.5% (3-5). Nevertheless, drugs
with convulsant properties may precipitate seizures, in
high risk patients such as the critically ill, and thus be
particularly a problem in the ICU setting (6).
Amongantimicrobials, the B-Iactamcompounds such
I
as the penicillinsland related antibiotics are frequently
cited as posing' a risk for inducing convulsions (0.5%),
and care should be made in the critically ill patient to
prescribe such medications only as necessary and in
appropriate doses for the patient's medical condition
(renal failure, congestive heart failure, liver disease)
(3,7). Renal insufficiency, in particular, appears to be an
important predisposing factor for B-Iactam drug
toxicity (7). Because oftheir action primarily as GABA
ant~gonists,benzodiazepines, not phenytoin, should be
considered as first line agents to combat B-Iactam drug
toxicity (7). Isoniazid (INH) is the second class of
antimicrobials frequently associated with seizure toxicity
occurring in 1-3%ofpatients, although quite uncommon
in therapeutic doses (3). Of importance, seizures from
this medication require administration of pyridoxine
to circumvent the antagonism of pyridoxal phosphate
by fNH.
Another class of pharmaceuticals commonly linked
to drug-induced seizure toxicity and as a cause of ICU
admissions are the psychotropic agents, particularly the
antidepressants. The relative risk for seizures ranges from
0.1-4% (8), and may be higher in select drugs. '
Although the vast majority ofseizures induced by these
medications occur following an overdose, the
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proconvulsant nature underlying their eNS effects is
cause for concern when treating critical ill patients.
Relative risk rates for some of these drugs have been
assigned, and one should select from the low risk
category ifadministering them to high risk patients. In
particular, the serotonin selective reuptake inhibitors as
well as trazodone, doxepin, and the MAO inhibitors
all have very'low potential for causing seizures,
the tricyclics and buproprion have an intermediate
risk, while maprotiline and amoxapine are considered
high risk (8).
Other pharmaceuticals used in the ICU that have a
noteworthy history ofdrug-induced seizures include the
phenothiazine, chlorpromazine (risk 3-5%) (3,9,10)
theophylline (risk 8-14% in theophylline toxic patients)
(11-13) and the local anesthetics. Theophylline-induced
seizures are distinct in thatthey may be refractory to the
typical first line anticonvulsant agents such as the
benzodiazepines, phenytoin, and phenobarbital (14, 15).
Although local anesthetics as a group may induce
seizures in toxic doses, lidocaine is mostoften the culprit
due to its ubiquitous use as an antiarrhythmic and in a
variety of forms for providing local anesthesia (spray,
topical, subcutaneous, intravenous, epidural, intrathecal).
The risk of seizures is dose dependent and correlates
well with serum concentration. Attherapeutic levels for
the treatment of arrhythmias and as an anesthetic
supplement (1-5 mg/L), the incidence of seizures is
very low, whereas at concentrations of 8-12 mg/L,
seizures become relatively common (16). Although
convulsions are usually a resultofhigh dose intravenous
injection ordirectly into the CNS as in spinal anesthesia,
seizures have been reported following intratracheal
instillation for bronchoscopy or even after topical
application (16-20).
In addition to medical causes, convulsive disorders
rank high as a complication ofhead injury. Seizures can
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Causes ofSeizures in the leU
Table-I
2. Complications ofcritical illness & management
Clinical Presentation and Diagnosis
Treatment
(including secondary generalization), with some reports
observing approximately 90% GTCS as the presenting
seizure type (1,2). These data suggest that seizure
diagnosis is rarely a diagnosticdilemma, even in the ICU,
Although uncommon, patients that presentwith complex-
partial seizures(9%)or non-convulsive statusepilepticus,
may be difficult to diagnose, especially with the host of
other critical care issues and sedatives administered, It
is this population of patients with either undiagnosed
recurrent seizures or frank refractory status epilepticus,
where the potential for irreversible neurological injury
is high. More recently, some investigators have evidence
to suggest that the incidenceofnon-convulsive seizures
is alarmingly high upto 34%of euro-ICU patients, and
it is only for a lack ofmonitoring that these seizures are
not detected (23), Therefore, it cannot be over-
emphasized that EEG oflCU patients is crucial in settings
where seizures may be a complicating feature ofcritical
illness,
Optimal treatment of seizures "' the ICU, involves
both the acute cessation of ictal activity and preventing
recurrence, ideally by removing or correcting the
physiological trigger and providing pharmacological
prophylaxisagainst recurrence. Mostcommonly, seizures
manifestas singleepisodes which serve to alert the care
givers in dramatic fashion that a metabolic or structural
abnormality exists,
For immediate treatment ofseizures, benzodiazepines
are considered the first lineoftreatment. They penetrate
into brain rapidly, are potent GABA agonists, and serve
to improve local inhibition of signal transmission.
Commonly used benzodiazepines include diazepam,
midazolam, or lorazepam. Each has a unique
pharmacokinetic profile. Diazepam has been the popular
standard, although its use against seizures is waning
owingto the superior propertiesoftheothertwo, HighIy
- Stroke
- Malformation
- Hemorrhage
- Vasculitis
• Neurovascular disease
- Cerebral contusion
- Cerebral hemorrhage
• Tumors - Primary
- Secondary
• eNS Infections ;-
- Abscess
- Meningitis
- Encephalitis
- Cerebral malaria
• Primary Epilepsy
• Metabolic disturbances
• Head injury
L Primary curological Pathology
manifest either early in thecourse«I week) ordevelop
during the late recovery period or following discharge.
Although a recent population-based study observed a
2, I% incidence of seizures following recovery from
head injury (21), the incidenceofearly seizures appears
to be higher. Almost halfofthe seizures occurred during
the first 24 hI's, Once a seizure occurs, especially ifit is
of late onset (> I week), the risk of recurrence is high,
approaching 90% (22). Late onset seizures are also a
greater predictorofsignificant long term morbidity and
poor outcome than those occurring early in the post-
injury phase.
• I-Iypoxia/Ischcmia
• Drug toxicity
• Infection-fever
• Metabolic abnormalities
• Renal/hepatic dysfunctions
• Surgical injury
Most seizures that occur in an ICU setting manifest
as focal or generalized tonic-clonic convulsions
(GTCS). By far, the mostcommon seizure type is GTCS
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lipophilic, diazepam rapidly redistributesaway from the
serum into fat. The result is that its effective
anticonvulsant duration is on the order of only a few
minutes, although its elimination time from the body is
many hoursand the longestofthe three agents (24). Such
kinetics could possibly result in briefseizure control yet
a prolonged sedative effect if1arge dosages are required.
Midazolam is also highly lipophilicand short acting, but
is cleared by the liver much more rapidly than diazepam
(>lOx) resulting in bettercorrelation between drugeffect
and clearance(25). Lorazepam, a compound with greater
water solubility that prolongs its serum half-life, is
clinically effective for several hours (26). In a recent
randomizcd controlled trial with patients in status
epilepticus, lorazepam was found to be superior than
diazepam or phenytoin alone in terminatingclinical and
EEG seizures (26). Thus, it is reasonable to use
lorazepam to the treatment ofall GTCS in the ICU since
rapid, maximal control is desired. In patients in whom
prolonged sedation may seriouslyconfound neurological
management, initial treatment of seizures may be
instituted with a short acting benzodiazepine to be
followed immediately by a loading dose ofphenytoin.
Once seizures are controlled, monotherapy with
phenytoin for seizures is advocated to lessen the
complications of drug interactions. Seizure recurrence
should be managed first with acute treatment, again
typically \\ ith benzodiazepines, followed by increasing
serulll concentrations of the primary anticonvulsant to
high or maximal therapeutic levels. Should seizures
become refractory, continuous EEG monitoring,
intravenous phenytoin or inhalational anesthetics are
recommended.
As alluded to earlier, it is important to realize that
seizures occurring in the ICU setting may have unusual
causes with complex features and treatments.
Convulsions from theophylline toxicity carry a risk of
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morbidity and mortality that may exceed 40% (27) and
part of the reason may be due to the fact that these
seizures can be refractory to conventional anticonvulsant
regimens (3). Repetitive seizures and status epilepticus
may result. Hemoperfusion, dialysis, and activated
charcoal all have their advocates for acute therapy, and
some experts believe aggressive measures be initiated if
theophylline serum levels reach 100 Jlg/ml (6,14,28).
Isoniazid is anotherdrugthat requires non-conventional
therapeutics. Due to its action as an antagonist to
pyridoxal phosphate, treatment includes intravenous
pyridoxine (3,29).
Treatment of other drug-induced seizures generall)
respond to benzodiazepines or barbiturates, and these
should be considered first Iine options (7). Phenytoin is
not particularly effective against most drug-induced
convulsions, especially those triggered by B-Iactam
antibiotics. Hemodialysis may be a consideration if
seizures are recurrent, particularly if renal failure
complicates drug elimination.
Toxicity ofAnticonvulsantTherapy
It must be kept in mind that there is no medical benefit
without risk, and the initiation of anticonvulsant
medications potentially introduces additional drug·
induced side-effects to a critically ill patient. Both
idiosyncratic and dose-dependent complications of
therapymayoccurand should be monitored for. Toxicit)
from anticonvulsants in ICU patients are predominantl)
a result of coexisting hepatic and renal dysfunction.
Drugs slIch as phenytoin, carbamazepine, a~ld valproic
acid are heavily protein bound, and free serum drug is
theactive moiety. Therefore, in critical illness that alters
serum protein levels, free drug concentrations may be
severely increased even in the face of normal total
serum drug concentrations. Routine monitoring of
free drug levels is expensive, but warranted in such
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patients. Hepatic dysfunction is less of a concern with
phenobarbital (30).
The most common dose-dependent side-effects of
31lticol1vulsants are sedation and mild cognitive
impairment, even in therapeutic concentrations and
particularly in the elderly and seriously ill. Ataxia
and brainstem dysfunction may be a resultofphenytoin
or carbamazepine toxicity, while valproate induces
tremors. Carbamazepine toxicity may present in biphasic
fashion: acutely and subsequently as a consequence of
increasing levels ofthetoxic intermediate 10-11 epoxide
metabolise (30). Additional common acute, dose-
dependent toxicities include transient leukopenia
and thrombocytopenia (carbamazepine/valproate),
megaloblastic anemia (phenytoin), and Syndrome of
Inappropriate ADH Secretion-SIADH (carbamazepine).
Renal disease also may significantly perturb
the clearance of anticonvulsants, although commonly
only when the glomerular filtration rate falls belo\\
10 mUmin (30). Phenobarbital and carbamazepine are
not greatly affected, but phenytoin and valproate serum
levels can rise or fall, and free levels in these cases may
be a beller guide due to the higher protein binding
exhibited by these agents(30). Duringdialysis, phenytoin
levels are not dramatically affected as is the case with
phenobarbital. Other drugs may impede normal
metabolism of 31lticonvuls31lts slich as cimetidine,
erythromycin, calcium channel blockers, coumadin
sulfonamides, and amiodarone (30).
Idiosyncratic reactions ofanticonvulsants may
contribute to the morbidity of critical ill patients.
Ilypersensitivity is relatively common with agents such
as phenytoin andcarbamazepinewith clinical features.of
fever, rash and eosinophilia (31). Other drug effects
that may occur (all are uncommon) include hepatic
failure, pancreatitis (particularly valproate),
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agranulocytosis, aplastic anemia, Stevens-Johnson
syndrome, and a Lupus-like syndrome (30). Severe
hepatic dysfunction may rarely occur with valproate
therepysecondaryto a toxic metabolic intermediate. This
potentially fatal action is best correlated in children under
two years of age receiving polypharmacy for seizure
control, and aspirin (32).
Prophylactic Therapy for Seizures
Patients in the ICU frequently suffer from a cerebral
disturbance which carries a risk ofseizures. Thus the
issue is raised whether the benefitofseizure prevention
outweighs its potential toxicity. As stated earlier, many
seizures in the ICU are mailifestations of transient
metabolic or physiological abnormalities and the risk of
recurrence is low ifhomeostasis is restored. For patients
with physical pathology of the C S, however, the risk
ofrecurrence is frequently high.
Cerebrovascular accidents are a precipitating cause
of seizures in 3-6% of patients (33, 34). Whether all
stroke patients, as a group, should receive prophylactic
anticonvulsant therapy has not been fully established.
Hemorrhagic stroke carries a two-fold increase in the
risk ofseizures compared to ischemic infarction. Thus
elderly patients, who are confusedat the beginning and
those whodo have an early seizure« I week afterstroke)
have a high risk of recurrence and should therefore be
considered for prophylactic therapy (34).
Patients with an intracranial tumorare at high risk for
seizures, and are frequently prescribed prophylactic
seizure medication. It is known for certain that patients
with cerebral tumors, particularly gliomas, have a high
recurrence rateofseizures. Once they occur, prophylactic
therapy is mandated, although incompletel) effective in
more than 25% ofcases (35). In case ofhead injury, as
stated previously, the risk ofseizures in early post-trauma
period is approximately 4%. Offered appropriate
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patients. Hepatic dysfunction is less ofa concern with
phenobarbital (30).
The most common dose-dependent side-effects of
anticonvuls3nts are sedation and mild cognitive
impairment, even in therapeutic concentrations and
particularly in the elderly and seriously ill. Ataxia
and brainstem dysfunction may be a resultofphenytoin
or carbamazepine toxicity, while valproate induces
Iremors. Carbamazepinetoxicity may present in biphasic
fashion: acutely and subsequently as a consequence of
increasing levels ofthe toxic intermediate 10-11 epoxide
metabolise (30). Additional common acute, dose-
dependent toxicities include transient leukopenia
and thrombocytopenia (carbamazepine/valproate),
megaloblastic anemia (phenytoin), and Syndrome of
Inappropriate ADH Secretion-SIADI-I (carbamazepine).
Renal disease also may significantly perturb
the clearance of anticonvulsants, although commonly
only when the glomerular filtration rate falls below
10 mL!min (30). Phenobarbital and carbamazepine are
AJ&!d!':ealJyaffected, but phenytoin and valproate serum
levels can rise or fall, and free levels in these cases may
be a better guide due to the higher protein binding
exhibited by theseagents(30). Duringdialysis, phenytoin
levels are not dramatically affected as is the case with
phenobarbital. Other drugs may impede normal
metabolism of 31lticollvulsallts slich as cimetidine,
erythromycin, calcium channel blockers, cOllllladin
sulfonamides, and ami6darone (30).
Idiosyncratic reactions of anticonvuIsants may
contribute to the morbidity of critical ill patients.
Hypersensitivity is relatively common with agents such
as phenytoin andcarbamazepinewith clinical features.of
fever, rash and eosinophilia (31). Other drug effects
that may occur (all are uncommon) include hepatic
failure, pancreatitis (particularly valproate),
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agranulocytosis, aplastic anemia, Stevens-Johnson
syndrome, and a Lupus-like syndrome (30). Severe
hepatic dysfunction may rarely occur with valproate
therepy secondarytoa toxic metabolic intermediate. This
potentiallyfatal action is bestcorrelated in children under
two years of age receiving polypharmacy for seizure
control, and aspirin (32).
Prophylactic Therapy for Seizures
Patients in the ICU frequently sufferfrom a cerebral
disturbance which carries a risk ofseizures. Thus the
issue is raised whether the benefitofseizure prevention
outweighs its potential toxicity. As stated earlier, many
seizures in the ICU are manifestations of transient
metabolic or physiological abnormalities and the risk of
recurrence is low ifhomeostasis is restored. For patients
with physical pathology ofthe CNS, however, the risk
ofrecurrence is frequently high.
Cerebrovascular accidents are a precipitating cause
of seizures in 3-6% of patients (33, 34). Whether all
stroke patients, as a group, should receive prophylactic
anticonvulsant therapy has not been fully established.
Hemorrhagic stroke carries a two-fold increase in the
risk ofseizures compared to ischemic infarction. Thus
elderly patients, who are confusedat the beginning and
thosewho do have an early seizure« I week afterstroke)
have a high risk of recurrence and should therefore be
considered for prophylactic therapy (34).
Patients with an intracranial tumorare at high risk for
seizures, and are frequently prescribed prophylactic
seizure medication. It is known for certain that patients
with cerebral tumors, palticularly gliomas, have a high
recurrence rateofseizures. Oncethey occur, prophylactic
therapy is mandated, although incompletely effective in
more than 25% ofcases (35). In case ofhead injury, as
stated previousIy, the risk ofseizures in early post-trauma
period is approximately 4%. Offered appropriate
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treatment, reports suggest that the occurrence of a
seizure does not influence the ultimate neurological
recovery(36). Prophylaxisagainstseizures has notbeen
demonstrated to prevent the possibility of epilepsy
following recovery in a prospective cohort. However,
the likelihood of further seizures and neurological
deterioration does supportaggressivetreatmentfollowing
an initial convulsion (22).
Personal Experience in the JCU
We followed up 52 cases of seizures who were
admilted at different occasions in the ICU and following
observations were made:-
I. Metabolic abnormalities causing seizures 14
2. Post anoxic 12
3. Infections (Encephalitis, Meningites, 09
Cereberal malaria)
4. Primary Epilepsy 07
5. Poisonings 05
6. No cause could be found 05
Conclusion
Treatment of seizures in an ICU setting can be a
challenging engagement. The difficulties of seizure
diagnosis and treatment that present themselves when
caring for critically ill patients can be daunting. The use
of a variety of medications and intensive care
management tend to lower, rather than elevate seizure
threshold. The seizure may itself be subtle and require
electrical confirmation, and the causative factor may be
difficultto assign with confidence. Treatmentofseizures
is important, however, due to their potential for further
neurological injury. Proper'assessment of the risk for
seizures in critically ill patients is also important, owing
to the potential for anticonvulsant-induced toxicity.
Decisions regarding prophylaxis are based on a
toxicity/benefit analysis permitting a logical approach
toward the prevention of seizures and optimizing
neurological recovery in the ICU and during later
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recovery. Personal experience saysthat in an ICU setting
one should always find out the cause like metabolic,
infections, poisonings which if not searched may go
undetected and poses a dangerous situation for the
patient.
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